GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NervGen Pharma Corp (OTCPK:NGENF) » Definitions » EV-to-EBITDA

NervGen Pharma (NervGen Pharma) EV-to-EBITDA : -5.87 (As of May. 01, 2024)


View and export this data going back to 2019. Start your Free Trial

What is NervGen Pharma EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, NervGen Pharma's enterprise value is $97.08 Mil. NervGen Pharma's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $-16.53 Mil. Therefore, NervGen Pharma's EV-to-EBITDA for today is -5.87.

The historical rank and industry rank for NervGen Pharma's EV-to-EBITDA or its related term are showing as below:

NGENF' s EV-to-EBITDA Range Over the Past 10 Years
Min: -38.71   Med: 0   Max: 0
Current: -5.87

NGENF's EV-to-EBITDA is ranked worse than
100% of 469 companies
in the Biotechnology industry
Industry Median: 9.09 vs NGENF: -5.87

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-01), NervGen Pharma's stock price is $1.52. NervGen Pharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.282. Therefore, NervGen Pharma's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


NervGen Pharma EV-to-EBITDA Historical Data

The historical data trend for NervGen Pharma's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NervGen Pharma EV-to-EBITDA Chart

NervGen Pharma Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBITDA
Get a 7-Day Free Trial -5.52 -6.53 -8.61 -3.58 -6.72

NervGen Pharma Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.58 -4.00 -4.46 -5.09 -6.72

Competitive Comparison of NervGen Pharma's EV-to-EBITDA

For the Biotechnology subindustry, NervGen Pharma's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NervGen Pharma's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NervGen Pharma's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where NervGen Pharma's EV-to-EBITDA falls into.



NervGen Pharma EV-to-EBITDA Calculation

NervGen Pharma's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=97.081/-16.527
=-5.87

NervGen Pharma's current Enterprise Value is $97.08 Mil.
NervGen Pharma's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-16.53 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


NervGen Pharma  (OTCPK:NGENF) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

NervGen Pharma's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=1.52/-0.282
=At Loss

NervGen Pharma's share price for today is $1.52.
NervGen Pharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.282.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


NervGen Pharma EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of NervGen Pharma's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


NervGen Pharma (NervGen Pharma) Business Description

Traded in Other Exchanges
Address
2955 Virtual Way, Suite 480, Vancouver, BC, CAN, V5M 4X6
NervGen Pharma Corp is a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases. The company is developing drugs for the treatment of spinal cord injury, multiple sclerosis, and Alzheimer's disease. It operates in a single segment, which is the research and development of pharmaceutical drugs.

NervGen Pharma (NervGen Pharma) Headlines

From GuruFocus